ECC 2015 | Biomarker-driven therapies for triple-negative breast cancer

Giuseppe Curigliano

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter